News | April 02, 2009

Results of Two Studies on Counterpulsation Therapy to Promote Collateral Growth Presented at the ACC

April 2, 2009 - Vasomedical Inc. this week conducted two presentations on the beneficial effects of EECP external counterpulsation therapy at the 58th Annual Scientific Session of the American College of Cardiology (ACC) in Orlando.

The external EECP counterpulsation therapy is a noninvasive, outpatient therapy used in the treatment of ischemic cardiovascular diseases, currently used to manage chronic stable angina and heart failure. The therapy increases blood flow and oxygen supply to the heart muscle and other organs and decreases the heart's workload and need for oxygen. Function of the endothelium, the inner lining of blood vessels throughout the body, is also improved, lessening resistance to blood flow. These actions reduce or eliminate symptoms of angina and heart failure, the company said.

The first presentation by Randy W. Braith, M.D., Richard C. Conti, M.D., and colleagues from the University of Florida in Gainesville demonstrated that EECP therapy significantly improves brachial flow-mediated dilation, reduces arterial stiffness, increases nitric oxide release, exercise duration and peak oxygen consumption while there are no significant changes in the control group with low pressure sham EECP treatment. The consistency of all parameters examined in this study involving non-invasive measurements of endothelial functions by a world-class team of scientists, researchers, and clinicians confirms that EECP therapy improves peripheral endothelial function and reduces arterial stiffness. These vascular adaptations decrease left ventricular afterload and myocardial oxygen demand, and increase anginal threshold in patients with refractory angina.

The second presentation by Steffen Gloekler, M.D., and colleagues from University Hospital in Bern, Switzerland showed EECP therapy promotes coronary collateral growth (arteriogenesis) in a single-blinded, sham-controlled study of 15 coronary artery disease (CAD) patients, treated for 30 hours at two-hours per daily session. Nine patients received EECP treatment with 300 mmHg of cuff inflation pressure (EECP group), six with 80 mmHg inflation pressure (sham group). Invasive coronary collateral assessment was performed at baseline and after EECP therapy using the Collateral Flow Index (CFI); a ratio of mean occlusive pressure determined invasively using a pressure guidewire distal to the balloon-occluded coronary artery and the mean aortic pressure. In the EECP group, CFI changed from 0.122 ± 0.06 to 0.210 ± 0.07, p=0.0002, and in the sham group from 0.165 ± 0.08 to 0.130 ± 0.06, p=0.04. The active EECP treatment induced a difference of CFI of 0.088 ± 0.07 versus –0.044 ± 0.07 in the sham group (p=0.00005). The study concluded that the clinical benefit of EECP for CAD patients might be explained by its arteriogenetic effect due to the increased laminar shear stress at the endothelial cell layer, improving endothelial function.

"The clinical effectiveness of EECP in the treatment of ischemic heart disease has been well established, but the multiple mechanisms of action (MOA) remain to be explored. The mounting evidence that EECP increases blood flow velocity and therefore the shear stress on the endothelium leading to improvement in endothelial function can now be recognized as one of the leading MOA. The two randomized-controlled studies presented during this ACC meeting provide definitive evidence to support the hypothesis that EECP improves endothelial function and enhances arteriogenesis by promoting collateral growth," Dr. Conti said.

For more information: www.acc.org, www.vasomedical.com

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init